Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Previously Untreated Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT06776770 is registered in ClinicalTrials.gov with Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center as lead sponsor.

NCT NCT06776770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06776770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Previously Untreated Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 3, 2024
Completion date
December 31, 2026
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer